ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,447.00
0.57%
S&P ASX All Technology
3,917.90
1.35%
Brent Oil
75.915
-0.91%
US Dollar vs AUD
1.60844
0.58%
Bitcoin
102,123.26
0.78%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Clearside Biomedical Inc (CLSD) Share Price

Clearside Biomedical Inc

Clearside Biomedical Inc (CLSD)

NASDAQ
0.9201
-0.0079
(-0.85%)
Closed 29 January 8:00AM
Delayed by 15 minutes
0.9201
0.00
( 0.00% )
Pre Market: 11:00PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.9201
Bid
0.921
Offer
0.95
Volume
25
0.00 Day's Range 0.00
0.801 52 Week Range 2.12
Market Cap
69.784M
Previous Close
0.9201
Open
-
Last Trade
2
@
0.93
Last Trade Time
00:50:06
Financial Volume
-
VWAP
-
Average Volume (3m)
256,661
Shares Outstanding
75,843,504
Dividend Yield
-
PE Ratio
-2.15
Earnings Per Share (EPS)
-0.43
Revenue
8.23M
Net Profit
-32.49M

About Clearside Biomedical Inc

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual functio... Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.clearsidebio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Clearside Biomedical Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CLSD. The last closing price for Clearside Biomedical was US$0.92. Over the last year, Clearside Biomedical shares have traded in a share price range of US$ 0.801 to US$ 2.12.

Clearside Biomedical currently has 75,843,504 shares in issue. The market capitalisation of Clearside Biomedical is US$69.78 million. Clearside Biomedical has a price to earnings ratio (PE ratio) of -2.15.

Ask ADVFN Intelligence (AI)

CLSD Latest News

More News

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery andĀ Key Differentiators in its CLS-AX Clinical Program

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to FeatureĀ CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with...

28 January 2025
GlobeNewswire Inc.

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

- ARCATUSĀ®, Branded as XIPEREĀ® in the U.S., is the First Globally Approved Suprachoroidal Therapy - - Continued Global Expansion of Clearsideā€™s Suprachoroidal Space Injection Platform Featuring...

22 January 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

11 January 2025
Edgar (US Regulatory)

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.Ā (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

19 December 2024
GlobeNewswire Inc.

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting...

25 November 2024
GlobeNewswire Inc.

Form 8-K - Current report

13 November 2024
Edgar (US Regulatory)

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a...

13 November 2024
GlobeNewswire Inc.

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearsideā€™s Suprachoroidal Space...

08 November 2024
GlobeNewswire Inc.

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.Ā (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

06 November 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

05 November 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0299-3.147368421050.950.97860.91275350.93407037CS
4-0.0399-4.156250.961.020.91385430.94978732CS
12-0.1499-14.00934579441.071.160.8012566610.99646923CS
26-0.2599-22.02542372881.181.650.8014990501.18348508CS
52-0.3199-25.79838709681.242.120.8013865281.27842783CS
156-0.9499-50.79679144391.872.850.6501013160011.46396664CS
260-2.2299-70.79047619053.157.730.6501015140532.97754497CS

CLSD - Frequently Asked Questions (FAQ)

What is the current Clearside Biomedical share price?
The current share price of Clearside Biomedical is US$ 0.9201
How many Clearside Biomedical shares are in issue?
Clearside Biomedical has 75,843,504 shares in issue
What is the market cap of Clearside Biomedical?
The market capitalisation of Clearside Biomedical is USD 69.78M
What is the 1 year trading range for Clearside Biomedical share price?
Clearside Biomedical has traded in the range of US$ 0.801 to US$ 2.12 during the past year
What is the PE ratio of Clearside Biomedical?
The price to earnings ratio of Clearside Biomedical is -2.15
What is the cash to sales ratio of Clearside Biomedical?
The cash to sales ratio of Clearside Biomedical is 8.48
What is the reporting currency for Clearside Biomedical?
Clearside Biomedical reports financial results in USD
What is the latest annual turnover for Clearside Biomedical?
The latest annual turnover of Clearside Biomedical is USD 8.23M
What is the latest annual profit for Clearside Biomedical?
The latest annual profit of Clearside Biomedical is USD -32.49M
What is the registered address of Clearside Biomedical?
The registered address for Clearside Biomedical is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Clearside Biomedical website address?
The website address for Clearside Biomedical is www.clearsidebio.com
Which industry sector does Clearside Biomedical operate in?
Clearside Biomedical operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OCEAOcean Biomedical Inc
US$ 0.64075
(94.17%)
38.93M
NOEMUCO2 Energy Transition Corporation
US$ 16.12
(57.27%)
6
SLXNSilexion Therapeutics Corporation
US$ 2.08
(54.07%)
65.52M
LGCLLucas GC Ltd
US$ 0.7943
(38.86%)
24.06M
EVTVEnvirotech Vehicles Inc
US$ 0.74
(30.05%)
32.77M
TMCITreace Medical Concepts Inc
US$ 5.01
(-47.01%)
11
CPSSConsumer Portfolio Services Inc
US$ 7.01
(-41.24%)
18
RILYTB Riley Financial Inc
US$ 6.00
(-37.66%)
1
AURAAura Biosciences Inc
US$ 5.02
(-36.05%)
1
ZKINZK International Group Co Ltd
US$ 0.565
(-30.99%)
626.64k
SLXNSilexion Therapeutics Corporation
US$ 2.08
(54.07%)
65.52M
OCEAOcean Biomedical Inc
US$ 0.64075
(94.17%)
38.93M
EVTVEnvirotech Vehicles Inc
US$ 0.74
(30.05%)
32.77M
SXTP60 Degrees Pharmaceuticals Inc
US$ 0.966
(25.32%)
32.15M
LGCLLucas GC Ltd
US$ 0.7943
(38.86%)
24.06M

CLSD Discussion

View Posts
georgie18 georgie18 1 month ago
CLSD...95...🥳...Setting up for $1.20 Break...imo...we shall see... https://schrts.co/nhFdXepw

CLSD...$1.45...🥳...ALPHARETTA, Ga., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet AMD) achieved both its primary and secondary outcomes. In participants who received CLS-AX delivered suprachoroidally, best corrected visual acuity (BCVA) and ocular anatomy (central subfield thickness) were stable up to 6 months compared to participants who received aflibercept. In addition, CLS-AX demonstrated a well-tolerated safety profile to Week 36 inclusive of mandatory re-dosing of CLS-AX at Week 24.
šŸ‘ļø0
Invest-in-America Invest-in-America 4 months ago
CLSD: Nice news for sure, but heavy FLOAT of 63-million..
šŸ‘ļø0
Awl416 Awl416 4 months ago
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
šŸ‘ļø0
BBANBOB BBANBOB 4 months ago
CLSD 1.52
šŸ‘ļø0
BBANBOB BBANBOB 5 months ago
CLSD under 1$ @ .9355
šŸ‘ļø0
Monksdream Monksdream 5 months ago
CLSD under $2
šŸ‘ļø0
Monksdream Monksdream 7 months ago
CLSD under $2
šŸ‘ļø0
Monksdream Monksdream 9 months ago
CLSD under $2
šŸ‘ļø0
BBANBOB BBANBOB 10 months ago
I'll suggest now that the GAP FILLED yesterday and it takes news 2-3 days to be digested, tomorrow we hopefully head back to the 2$ area, just my WAG bwthdik
šŸ‘ļø0
BBANBOB BBANBOB 11 months ago
WHO KNOWS PARD WHO KNOWS
👍️ 1
BBANBOB BBANBOB 11 months ago
.
šŸ‘ļø0
jhdf51 jhdf51 11 months ago
Great..well maybe just maybe we are finally on our way albeit perhaps a bumpy ride...

JHD
šŸ‘ļø0
BBANBOB BBANBOB 11 months ago
JHD

NOT really GAP filled and has held up very well, next surge is on its way and still say this will close on FRI over $2

Vol is holding UPPPPPPPP well so, something is up here, from 2.12 to 1.47 was a major head fake to close the gap imho and probably casue a lot to part with some shares WHIH imho is exactly what they wanted...............
šŸ‘ļø0
jhdf51 jhdf51 11 months ago
Same ol same ol
šŸ‘ļø0
BBANBOB BBANBOB 11 months ago
WE BOTH HAVE THE SAME PROBLEM

DNDN been there done that and not again
👍️ 1
BBANBOB BBANBOB 11 months ago
.53 cent loss versus .55 loss last yr
šŸ‘ļø0
jhdf51 jhdf51 11 months ago
Yep..I was thinking of getting out but same...
šŸ‘ļø0
BBANBOB BBANBOB 11 months ago
Not REAL THRILLED with the earnings to be released AH's that is normally indicative of bad numbers, so looks like the 2.12 was a head fake for some to get out
I came close to selling 50% yesterday and get back in when it closes the gap @ 1.54,,,,,,, but just couldn't find the CAJONES to do it..........OH WELL NO BALLS NO BLACK CHIPS
šŸ‘ļø0
BBANBOB BBANBOB 11 months ago
Appears they are playing this real hard to get shares all the way to 1.81 from 2.12
šŸ‘ļø0
BBANBOB BBANBOB 11 months ago
1.87 NEW annual high and HOD. 3 trade days ago we did 3 mill shares and VOL proceeds PPS

MY WAG is this is over 2$ by weeks end.

AND NO not pumping this since I have held it for over 2 yrs NOV of 2022 and @ $4.86 finally got my avg to $2.00
šŸ‘ļø0
Monksdream Monksdream 11 months ago
CLSD 10Q due March 12
šŸ‘ļø0
Monksdream Monksdream 11 months ago
CLSD new 52 week hi
šŸ‘ļø0
glenn1919 glenn1919 11 months ago
CLSD....................................................https://stockcharts.com/h-sc/ui?s=CLSD&p=W&b=5&g=0&id=p86431144783
šŸ‘ļø0
BBANBOB BBANBOB 11 months ago
And on VERY GOOD VOL, me thinks something is up
šŸ‘ļø0
Monksdream Monksdream 11 months ago
CLSD new 52 week high
šŸ‘ļø0
Monksdream Monksdream 11 months ago
CLSD under $2
šŸ‘ļø0
BBANBOB BBANBOB 1 year ago
OOOOOOOOOOOOOPS $1.47
šŸ‘ļø0
BBANBOB BBANBOB 1 year ago
OPPPPPPPPPPPPPPS .6951
šŸ‘ļø0
BBANBOB BBANBOB 1 year ago
APPEARS we just made a new one too DAMN @ .70

I'm hoping they are tanking it in front of good earning to pick it up I KNOWWWWWWWWWWWWWWWWWWWWWWWWWWWW
šŸ‘ļø0
Monksdream Monksdream 1 year ago
CLSD new 52 week low
šŸ‘ļø0
Monksdream Monksdream 1 year ago
CLSD new 52 week low
šŸ‘ļø0
Monksdream Monksdream 1 year ago
CLSD new 52 week low
šŸ‘ļø0
Monksdream Monksdream 1 year ago
CLSD new 52 week low
šŸ‘ļø0
heyitsmeagain heyitsmeagain 2 years ago
Here we go
šŸ‘ļø0
heyitsmeagain heyitsmeagain 2 years ago
Loaded for this runner. Wish I had more loot.
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
Hard to Borrow is back on CLSD today
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
FYI

THE HARD TO BORROW classification(at Schwab) just went POOF GHONDI as of today on CLSD and at the same time its is up 3.81%

HMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
Well so far so good !!!!!!!!!!!!!!!!!! Let's say for grins $3 on Fri
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
Well well let's give this news 2-3 days to digest and see where it is by weeks end.

Also if if if this is gonna take off as I believe, the first part of the week MIGHT JUST SCARE THE WEAK here.

If you're faint at heart or can't handle pressure, one might want to JUST NOT LOOK for the next few days
šŸ‘ļø0
jhdf51 jhdf51 3 years ago
Now that would be perfect. Iā€™d hire me a farm hand, or two, or three! Lol

JHD
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
Again

Earnings was a beat and they were .31 for the LAST quarter PER SHARE, do that X's a whole yr and then X's a multiple of 10-12 and there ya have it.

NOW Since this appears to be JUST the start of licensing, who knows how many more licenses will be entered into in the next year.

MY PPS prediction would be along the lines of $27-$35 in the next 12 months WAG and IMHO
šŸ‘ļø0
jhdf51 jhdf51 3 years ago
Yes I agree. Definitely could be. Dang Price targets are never exact anyway.
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
I'll take $9 for this year, but still say it will be more.
šŸ‘ļø0
jhdf51 jhdf51 3 years ago
I see $9. $18 was last year.

https://www.google.com/amp/s/www.marketbeat.com/instant-alerts/nasdaq-clsd-a-buy-or-sell-right-now-2022-03-2/amp/
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
But all companies good or bad always have HEDGE FUNDS that short their stock, THUS the meaning of HEDGE, being on both sides of the trade, much like a BOOKIE taking sports bets will take EITHER SIDE of a bet.

BUT unlike a bookie that takes your bet and at half time IS WAY UPSIDE down on the bet he made with you, HE DOES NOT HAVE THE OPPORTUNITY to CHANGE his bet, SHORTS DO at any given time

THUNK ABOUT IT BOYZZZZZZZZZZZ
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
SHORTS

Again as I did last week, I would serious suggest that you close even the few shorts you have still open here, as it might get REAL NASTY if ya don't, JUST SAYING
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
Having NOT been able to take part in PICKING UP SHARES last week, I just got back to even as of today at one point. IF IF IF it closes over 2.39 today, then FINALLY again I am BACK in the black.
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
Well YET AGAIN it seems my 3 day rule on it taking 3 days for news to be fully digested before a stock rises,has yet again proven itself true..
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
CRUDEOIL

I have always suggested on these boards that, ""IT TAKE 3 days for news to be really digested before ya see real up swings, HMMMMMMMM
šŸ‘ļø0
BBANBOB BBANBOB 3 years ago
OH I agree 100% and suggested that ALL for the last months JUST SIT ON THEIR HANDS or add.....

Me aint got no dry powder or I would have last week and large
šŸ‘ļø0

Your Recent History

NASDAQ
CLSD
Clearside Biomedical
COIN
MGXBTC
MEGA X
NYSE
BAI
BlackRock ETF Tr
BIT
F29099
Vontobel Financial Produ...
BIT
AI
Air Liquide
BIT
1FME
Fresenius Medical Care
BIT
F34657
Vontobel Financial Produ...
BIT
XPXJ
Xtrackers MSCI Pacific e...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads